Cited by 294Protein purification and stabilityBiosimilars and Bioanalytical MethodsMonoclonal and Polyclonal Antibodies Research

The DOI matches its Crossref record; 53 of the 54 references it cites were found in a registry or an index.

Determination of critical quality attributes for monoclonal antibodies using quality by design principles

Alt, Nadja, Zhang, Taylor Y., Motchnik, Paul, Taticek, Ron, Quarmby, Valerie, Schlothauer, Tilman, Beck, Hermann, Emrich, Thomas, Harris, Reed J.·2016·Biologicals

DOI 10.1016/j.biologicals.2016.06.005

Open this paper in CoChat — free account

Abstract

Quality by design (QbD) is a global regulatory initiative with the goal of enhancing pharmaceutical development through the proactive design of pharmaceutical manufacturing process and controls to consistently deliver the intended performance of the product. The principles of pharmaceutical development relevant to QbD are described in the ICH guidance documents (ICHQ8-11). An integrated set of risk assessments and their related elements developed at Roche/Genentech were designed to provide an overview of product and process knowledge for the production of a recombinant monoclonal antibody. This chapter describes the identification of critical quality attributes (CQAs) as an important first step for QbD development of biopharmaceuticals. A systematic scientific based risk ranking and filtering approach allows a thorough understanding of quality attributes and an assignment of criticality for their impact on drug safety and efficacy. To illustrate the application of the approach and tools, a few examples from monoclonal antibodies are shown. The identification of CQAs is a continuous process and will further drive the structure and function characterization of therapeutic proteins.

Integrity signals

Registry

Crossref · 10.1016/j.biologicals.2016.06.005

Cites

53 of 53 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Lack of Fucose on Human IgG1 N-Linked Oligosaccharide Improves Binding to Human FcγRIII and Antibody-dependent Cellular Toxicity
Shields, R. L., Lai, J., Keck, R., O'Connell, L. Y., Hong, K., Meng, Y. G., Weikert, S. H. A., & Presta, L. G. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202069200 · Cited by 1,835
Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-Galactose
Chung, C. H., Mirakhur, B., Chan, E., Le, Q.-T., Berlin, J., Morse, M., Murphy, B. A., Satinover, S. M., Hosen, J., Mauro, D., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa074943 · Cited by 1,521
The Absence of Fucose but Not the Presence of Galactose or Bisecting N-Acetylglucosamine of Human IgG1 Complex-type Oligosaccharides Shows the Critical Role of Enhancing Antibody-dependent Cellular Cytotoxicity
Shinkawa, T., Nakamura, K., Yamane, N., Shoji-Hosaka, E., Kanda, Y., Sakurada, M., Uchida, K., Anazawa, H., Satoh, M., Yamasaki, M., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210665200 · Cited by 1,413
Effects of protein aggregates: An immunologic perspective
Rosenberg, A. S. (2006) · The AAPS Journal · doi:10.1208/aapsj080359 · Cited by 1,355
Pure Red-Cell Aplasia and Antierythropoietin Antibodies in Patients Treated with Recombinant Erythropoietin
Casadevall, N., Nataf, J., Viron, B. M., Kolta, A. M., Kiladjian, J., Martin-Dupont, P., Michaud, P. A., Papo, T., Ugo, V., Teyssandier, I., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011931 · Cited by 1,244
Mistranslation-Induced Protein Misfolding as a Dominant Constraint on Coding-Sequence Evolution
Drummond, D. A., & Wilke, C. O. (2008) · Cell · doi:10.1016/j.cell.2008.05.042 · Cited by 1,065
THE COVALENT STRUCTURE OF AN ENTIRE γG IMMUNOGLOBULIN MOLECULE
Edelman, G. M., Cunningham, B. A., Gall, W. E., Gottlieb, P. D., Rutishauser, U. S., & Waxdal, M. J. (1969) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.63.1.78 · Cited by 903
Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity
Umaña, P., Jean–Mairet, J., Moudry, R., Amstutz, H., & Bailey, J. E. (1999) · Nature Biotechnology · doi:10.1038/6179 · Cited by 764
Immunogenicity of protein therapeutics
Groot, A. S. D., & Scott, D. W. (2007) · Trends in Immunology · doi:10.1016/j.it.2007.07.011 · Cited by 544
Identification of multiple sources of charge heterogeneity in a recombinant antibody
Harris, R. J., Kabakoff, B., Macchi, F. D., Shen, F. J., Kwong, M. Y., Andya, J. D., Shire, S. J., Bjork, N., Tótpál, K., & Chen, A. B. (2001) · Journal of Chromatography B Biomedical Sciences and Applications · doi:10.1016/s0378-4347(00)00548-x · Cited by 501
Self-citation

Flagged first, then by citations

Show all 54 references

1 of the 54 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, 2009

Sorted by citations

The making of bispecific antibodies
Brinkmann, U., & Kontermann, R. E. (2017) · mAbs · doi:10.1080/19420862.2016.1268307 · Cited by 961
Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins
Liming, L. (2017) · Protein & Cell · doi:10.1007/s13238-017-0408-4 · Cited by 407
Forced degradation of recombinant monoclonal antibodies: A practical guide
Nowak, C., Cheung, J. K., Dellatore, S. M., Katiyar, A., Bhat, R., Sun, J., Ponniah, G., Neill, A., Mason, B. D., Beck, A., et al. (2017) · mAbs · doi:10.1080/19420862.2017.1368602 · Cited by 262
Predicting antibody developability profiles through early stage discovery screening
Bailly, M., Mieczkowski, C., Juan, V., Metwally, E., Tomazela, D., Baker, J., Uchida, M., Kofman, E., Raoufi, F., Motlagh, S., et al. (2020) · mAbs · doi:10.1080/19420862.2020.1743053 · Cited by 228
Analytical methods for process and product characterization of recombinant adeno-associated virus-based gene therapies
Gimpel, A. L., Katsikis, G., Sha, S., Maloney, A. J., Hong, M. S., Nguyen, T. N. T., Wolfrum, J., Springs, S. L., Sinskey, A. J., Manalis, S. R., et al. (2021) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2021.02.010 · Cited by 185
Immunogenicity risk assessment and mitigation for engineered antibody and protein therapeutics
Carter, P. J., & Quarmby, V. E. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-01051-x · Cited by 117
Self-citation
The Hitchhiker’s Guide to Human Therapeutic Nanoparticle Development
Ramos, T. I., Villacis-Aguirre, C. A., López-Aguilar, K. V., Padilla, L. S., Altamirano, C., Toledo, J. R., & Vispo, N. S. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14020247 · Cited by 111
Science and art of protein formulation development
Wang, W., & Ohtake, S. (2019) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2019.118505 · Cited by 106
The physico-chemical landscape of extracellular vesicles
Manno, M., Bongiovanni, A., Margolis, L. B., Bergese, P., & Arosio, P. (2024) · Nature Reviews Bioengineering · doi:10.1038/s44222-024-00255-5 · Cited by 114
Analytical comparability study of recombinant monoclonal antibody therapeutics
Ambrogelly, A., Gozo, S., Katiyar, A., Dellatore, S. M., Kune, Y., Bhat, R., Sun, J., Li, N., Wang, D., Nowak, C., et al. (2018) · mAbs · doi:10.1080/19420862.2018.1438797 · Cited by 102
The yeast stands alone: the future of protein biologic production
Love, K. R., Dalvie, N. C., & Love, J. C. (2017) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2017.12.010 · Cited by 97
Hydrophilic Interaction Chromatography Hyphenated with Mass Spectrometry: A Powerful Analytical Tool for the Comparison of Originator and Biosimilar Therapeutic Monoclonal Antibodies at the Middle-up Level of Analysis
D’Atri, V., Fekete, S., Beck, A., Lauber, M. A., & Guillarme, D. (2017) · Analytical Chemistry · doi:10.1021/acs.analchem.6b04726 · Cited by 101
In vitro model for predicting bioavailability of subcutaneously injected monoclonal antibodies
Bown, H. K., Bonn, C., Yohe, S. T., Yadav, D. B., Patapoff, T. W., Daugherty, A. L., & Mrsny, R. J. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.01.015 · Cited by 92
Quality by Design (QbD) application for the pharmaceutical development process
Lee, S.-H., Kim, J., Jee, J., Jang, D.-J., Park, Y.-J., & Kim, J.-E. (2022) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-022-00575-x · Cited by 88
Multi-dimensional LC-MS: the next generation characterization of antibody-based therapeutics by unified online bottom-up, middle-up and intact approaches
Camperi, J., Goyon, A., Guillarme, D., Zhang, K., & Stella, C. (2020) · The Analyst · doi:10.1039/d0an01963a · Cited by 85
Molecular and functional analysis of monoclonal antibodies in support of biologics development
Wang, X., An, Z., Luo, W., Xia, N., & Zhao, Q. (2017) · Protein & Cell · doi:10.1007/s13238-017-0447-x · Cited by 82
Assessment of susceptible chemical modification sites of trastuzumab and endogenous human immunoglobulins at physiological conditions
Schmid, I., Bonnington, L. S., Gerl, M., Bomans, K., Thaller, A., Wagner, K., Schlothauer, T., Falkenstein, R., Zimmermann, B., Kopitz, J., et al. (2018) · Communications Biology · doi:10.1038/s42003-018-0032-8 · Cited by 79
Self-citation
Process characterization and Design Space definition
Hakemeyer, C., McKnight, N., John, R. S., Meier, S. J., Trexler‐Schmidt, M., Kelley, B. D., Zettl, F., Puskeiler, R., Kleinjans, A., Lim, F., et al. (2016) · Biologicals · doi:10.1016/j.biologicals.2016.06.004 · Cited by 77
A Quadrupole Dalton-based multi-attribute method for product characterization, process development, and quality control of therapeutic proteins
Xu, W., Jimenez, R. B., Mowery, R., Luo, H., Cao, M., Agarwal, N., Ramos, I., Wang, X., & Wang, J. (2017) · mAbs · doi:10.1080/19420862.2017.1364326 · Cited by 72
Trends in industrialization of biotherapeutics: a survey of product characteristics of 89 antibody-based biotherapeutics
Martin, K., Grimaldi, C. M., Grempler, R., Hansel, S. B., & Kumar, S. (2023) · mAbs · doi:10.1080/19420862.2023.2191301 · Cited by 67
Industrial bioprocessing perspectives on managing therapeutic protein charge variant profiles
Chung, S., Tian, J., Tan, Z., Chen, J., Lee, J., Borys, M., & Li, Z. J. (2018) · Biotechnology and Bioengineering · doi:10.1002/bit.26587 · Cited by 66
Stress Factors in mAb Drug Substance Production Processes: Critical Assessment of Impact on Product Quality and Control Strategy
Das, T. K., Narhi, L. O., Sreedhara, A., Menzen, T., Grapentin, C., Chou, D. K., Antochshuk, V., & Filipe, V. (2019) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2019.09.023 · Cited by 72
Fc galactosylation follows consecutive reaction kinetics and enhances immunoglobulin G hexamerization for complement activation
Wei, B., Gao, X., Cadang, L., Izadi, S., Liu, P., Zhang, H., Hecht, E. S., Shim, J., Magill, G., Pabon, J. P. R., et al. (2021) · mAbs · doi:10.1080/19420862.2021.1893427 · Cited by 65
Process Analytical Technology for Advanced Process Control in Biologics Manufacturing with the Aid of Macroscopic Kinetic Modeling
Kornecki, M., & Strube, J. (2018) · Bioengineering · doi:10.3390/bioengineering5010025 · Cited by 61
Mass spectrometry-based multi-attribute method in protein therapeutics product quality monitoring and quality control
Yang, F., Zhang, J., Buettner, A., Vosika, E., Sadek, M., Hao, Z., Reusch, D., Koenig, M., Chan, W., Bathke, A., et al. (2023) · mAbs · doi:10.1080/19420862.2023.2197668 · Cited by 55
Self-citation
Introduction to the application of QbD principles for the development of monoclonal antibodies
Finkler, C., & KRUMMEN, L. A. (2016) · Biologicals · doi:10.1016/j.biologicals.2016.07.004 · Cited by 55
Antibody-Drug Conjugate Overview: a State-of-the-art Manufacturing Process and Control Strategy
Li, M., Zhao, X., Yu, C., & Wang, L. (2024) · Pharmaceutical Research · doi:10.1007/s11095-023-03649-z · Cited by 54
In Translation: FcRn across the Therapeutic Spectrum
Qi, T., & Cao, Y. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22063048 · Cited by 59
Integrative overview of antibodies against SARS-CoV-2 and their possible applications in COVID-19 prophylaxis and treatment
Valdez‐Cruz, N. A., García‐Hernández, E., Espitia, C., Cobos-Marín, L., Altamirano, C., Bando-Campos, C. G., Cofas‐Vargas, L. F., Coronado-Aceves, E. W., González-Hernández, R. A., Hernández‐Peralta, P., et al. (2021) · Microbial Cell Factories · doi:10.1186/s12934-021-01576-5 · Cited by 52
Host Cell Proteins in Biologics Manufacturing: The Good, the Bad, and the Ugly
Kornecki, M., Mestmäcker, F., Zobel‐Roos, S., de Figueiredo, L. H., Schlüter, H., & Strube, J. (2017) · Antibodies · doi:10.3390/antib6030013 · Cited by 54
Denaturing and Native Mass Spectrometric Analytics for Biotherapeutic Drug Discovery Research: Historical, Current, and Future Personal Perspectives
Campuzano, I. D. G., & Sandoval, W. N. (2021) · Journal of the American Society for Mass Spectrometry · doi:10.1021/jasms.1c00036 · Cited by 51
Integration of QbD risk assessment tools and overall risk management
Kelley, B. D., Cromwell, M. E. M., & Jerkins, J. (2016) · Biologicals · doi:10.1016/j.biologicals.2016.06.001 · Cited by 51
From cell line development to the formulated drug product: The art of manufacturing therapeutic monoclonal antibodies
Carrara, S. C., Ulitzka, M., Grzeschik, J., Kornmann, H., Hock, B. M., & Kolmar, H. (2020) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2020.120164 · Cited by 52
Establishing a control system using QbD principles
Kepert, J. F., Cromwell, M. E. M., Engler, N., Finkler, C., Gellermann, G. P., Gennaro, L. A., Harris, R. J., Iverson, R., Kelley, B. D., KRUMMEN, L. A., et al. (2016) · Biologicals · doi:10.1016/j.biologicals.2016.06.003 · Cited by 47
Self-citation
Process analytical technology as key‐enabler for digital twins in continuous biomanufacturing
Schmidt, A., Helgers, H., Lohmann, L. J., Vetter, F. L., Juckers, A., Mouellef, M., Zobel‐Roos, S., & Strube, J. (2021) · Journal of Chemical Technology & Biotechnology · doi:10.1002/jctb.7008 · Cited by 45
Recent Advances in LC–MS Based Characterization of Protein‐Based Bio‐Therapeutics—Mastering Analytical Challenges Posed by the Increasing Format Complexity
Graf, T., Heinrich, K., Grunert, I., Wegele, H., Haberger, M., Bulau, P., & Leiss, M. (2020) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2020.113251 · Cited by 46
Physicochemical and functional assessments demonstrating analytical similarity between rituximab biosimilar HLX01 and the MabThera®
Xu, Y., Xie, L., Zhang, E., Gao, W., Wang, L., Cao, Y., Xie, M. H., Jiang, W., & Liu, S. (2019) · mAbs · doi:10.1080/19420862.2019.1578147 · Cited by 44
ID–MAM: A Validated Identity and Multi-Attribute Monitoring Method for Commercial Release and Stability Testing of a Bispecific Antibody
Evans, A. R., Hebert, A. S., Mulholland, J., Lewis, M. J., & Hu, P. (2021) · Analytical Chemistry · doi:10.1021/acs.analchem.1c01029 · Cited by 43
Fast and Automated Characterization of Monoclonal Antibody Minor Variants from Cell Cultures by Combined Protein-A and Multidimensional LC/MS Methodologies
Camperi, J., Dai, L., Guillarme, D., & Stella, C. (2020) · Analytical Chemistry · doi:10.1021/acs.analchem.0c01250 · Cited by 43
Risk-Based Control Strategies of Recombinant Monoclonal Antibody Charge Variants
Beck, A., Nowak, C., Meshulam, D., Reynolds, K., Chen, D. J., Pacardo, D. B., Nicholls, S. B., Carven, G. J., Gu, Z., Fang, J., et al. (2022) · Antibodies · doi:10.3390/antib11040073 · Cited by 43
Current challenges and recent advances on the path towards continuous biomanufacturing
Drobnjaković, M., Hart, R., Kulvatunyou, B., Ivezic, N., & Srinivasan, V. (2023) · Biotechnology Progress · doi:10.1002/btpr.3378 · Cited by 45
Building blocks for bispecific and trispecific antibodies
Wu, X., & Demarest, S. J. (2018) · Methods · doi:10.1016/j.ymeth.2018.08.010 · Cited by 43
Demonstrating Analytical Similarity of Trastuzumab Biosimilar HLX02 to Herceptin® with a Panel of Sensitive and Orthogonal Methods Including a Novel FcγRIIIa Affinity Chromatography Technology
Xie, L., Zhang, E., Xu, Y., Gao, W., Wang, L., Xie, M. H., Qin, P., Lu, L., Li, S., Shen, P., et al. (2020) · BioDrugs · doi:10.1007/s40259-020-00407-0 · Cited by 42
Glycosylation of Therapeutic Proteins: A Critical Quality Attribute
Delobel, A. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1241-5_1 · Cited by 42
Stability of Protein Pharmaceuticals: Recent Advances
Manning, M. C., Holcomb, R. E., Payne, R. W., Stillahn, J. M., Connolly, B. D., Katayama, D. S., Liu, H., Matsuura, J. E., Murphy, B. M., Henry, C. S., et al. (2024) · Pharmaceutical Research · doi:10.1007/s11095-024-03726-x · Cited by 45
Development of a 3D-LC/MS Workflow for Fast, Automated, and Effective Characterization of Glycosylation Patterns of Biotherapeutic Products
Camperi, J., Dai, L., Guillarme, D., & Stella, C. (2020) · Analytical Chemistry · doi:10.1021/acs.analchem.9b05193 · Cited by 41
Modulating cell culture oxidative stress reduces protein glycation and acidic charge variant formation
Chung, S., Tian, J., Tan, Z., Chen, J., Zhang, N., Huang, Y., Vandermark, E., Lee, J. C., Borys, M., & Li, Z. J. (2019) · mAbs · doi:10.1080/19420862.2018.1537533 · Cited by 38
Current Industry Best Practice on in-use Stability and Compatibility Studies for Biological Products
Blümel, M., Liu, J., de Jong, I., Weiser, S. E., Fast, J. L., Litowski, J. R., Shuman, M., Mehta, S. B., Amery, L., Tan, D. C. T., et al. (2023) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2023.05.002 · Cited by 39
A roadmap for model-based bioprocess development
Mu'azzam, K., da Silva, F. V. S., Murtagh, J., & Sousa-Gallagher, M. J. (2024) · Biotechnology Advances · doi:10.1016/j.biotechadv.2024.108378 · Cited by 40
Digital Twins for Continuous mRNA Production
Helgers, H., Hengelbrock, A., Schmidt, A., & Strube, J. (2021) · Processes · doi:10.3390/pr9111967 · Cited by 37
Process Automation and Control Strategy by Quality-by-Design in Total Continuous mRNA Manufacturing Platforms
Schmidt, A., Helgers, H., Vetter, F. L., Zobel‐Roos, S., Hengelbrock, A., & Strube, J. (2022) · Processes · doi:10.3390/pr10091783 · Cited by 38
Analytical characterization of coformulated antibodies as combination therapy
Kim, J., Kim, Y. J., Cao, M., Mel, N. D., Miller, K. W., Bee, J. S., Wang, J., Wang, X., & Albarghouthi, M. N. (2020) · mAbs · doi:10.1080/19420862.2020.1738691 · Cited by 36
QbD implementation and Post Approval Lifecycle Management (PALM)
Ohage, E. C., Iverson, R., KRUMMEN, L. A., Taticek, R., & Vega, M. (2016) · Biologicals · doi:10.1016/j.biologicals.2016.06.007 · Cited by 36
Self-citation
Quantification of protein glycation using vibrational spectroscopy
McAvan, B. S., France, A. P., Bellina, B., Barran, P. E., Goodacre, R., & Doig, A. J. (2020) · The Analyst · doi:10.1039/c9an02318f · Cited by 35
Intact multi-attribute method (iMAM): A flexible tool for the analysis of monoclonal antibodies
Carillo, S., Criscuolo, A., Füssl, F., Cook, K., & Bones, J. (2022) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2022.07.005 · Cited by 35
A cross-industry forum on benchmarking critical quality attribute identification and linkage to process characterization studies
Demmon, S. L., Bhargava, S., Ciolek, D., Halley, J., Jaya, N., Joubert, M. K., Koepf, E. K., Smith, P., Trexler‐Schmidt, M., & Tsai, P. (2020) · Biologicals · doi:10.1016/j.biologicals.2020.06.008 · Cited by 34
Hydrogen deuterium exchange and other mass spectrometry- based approaches for epitope mapping
Jethva, P. N., & Gross, M. L. (2023) · Frontiers in Analytical Science · doi:10.3389/frans.2023.1118749 · Cited by 37
Advances and applications of capillary electromigration methods in the analysis of therapeutic and diagnostic recombinant proteins – A Review
Stutz, H. (2022) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2022.115089 · Cited by 36
Accelerating Biomanufacturing by Modeling of Continuous Bioprocessing—Piloting Case Study of Monoclonal Antibody Manufacturing
Kornecki, M., Schmidt, A., Lohmann, L. J., Huter, M. J., Mestmäcker, F., Klepzig, L., Mouellef, M., Zobel‐Roos, S., & Strube, J. (2019) · Processes · doi:10.3390/pr7080495 · Cited by 32
Digital Twin for HIV-Gag VLP Production in HEK293 Cells
Hengelbrock, A., Helgers, H., Schmidt, A., Vetter, F. L., Juckers, A., Rosengarten, J. F., Stitz, J., & Strube, J. (2022) · Processes · doi:10.3390/pr10050866 · Cited by 32
Physicochemical and Biological Characterization of the Proposed Biosimilar Tocilizumab
Miao, S., Fan, L., Zhao, L., Ding, D., Liu, X., Wang, H., & Tan, W. (2017) · BioMed Research International · doi:10.1155/2017/4926168 · Cited by 31
Impact of IgG Fc‐Oligosaccharides on Recombinant Monoclonal Antibody Structure, Stability, Safety, and Efficacy
Liu, H., Nowak, C., Andrien, B. A., Shao, M., Ponniah, G., & Neill, A. (2017) · Biotechnology Progress · doi:10.1002/btpr.2498 · Cited by 32
A business analytics approach to augment six sigma problem solving: A biopharmaceutical manufacturing case study
Fahey, W., Jeffers, P., & Carroll, P. (2020) · Computers in Industry · doi:10.1016/j.compind.2019.103153 · Cited by 32
Quality by Design–Based Assessment for Analytical Similarity of Adalimumab Biosimilar HLX03 to Humira®
Zhang, E., Xie, L., Qin, P., Lu, L., Xu, Y., Gao, W., Wang, L., Xie, M. H., Jiang, W., & Liu, S. (2020) · The AAPS Journal · doi:10.1208/s12248-020-00454-z · Cited by 31
Inter-laboratory study to evaluate the performance of automated online characterization of antibody charge variants by multi-dimensional LC-MS/MS
Camperi, J., Grunert, I., Heinrich, K., Winter, M., Oezipek, S., Hoelterhoff, S., Weindl, T., Mayr, K., Bulau, P., Meier, M., et al. (2021) · Talanta · doi:10.1016/j.talanta.2021.122628 · Cited by 31
A high-resolution multi-attribute method for product characterization, process characterization, and quality control of therapeutic proteins
Guan, X., Eris, T., Zhang, L., Ren, D., Ricci, M. S., Thiel, T., & Goudar, C. T. (2022) · Analytical Biochemistry · doi:10.1016/j.ab.2022.114575 · Cited by 31
Added Value of Internal Fragments for Top-Down Mass Spectrometry of Intact Monoclonal Antibodies and Antibody–Drug Conjugates
Wei, B., Lantz, C., Liu, W., Viner, R., Loo, R. R. O., Campuzano, I. D. G., & Loo, J. A. (2023) · Analytical Chemistry · doi:10.1021/acs.analchem.3c01426 · Cited by 33
Investigation of monoclonal antibody dimers in a final formulated drug by separation techniques coupled to native mass spectrometry
Rouby, G., Tran, N. T., Leblanc, Y., Taverna, M., & Bihoreau, N. (2020) · mAbs · doi:10.1080/19420862.2020.1781743 · Cited by 30
Optimization of the quality by design approach for gene therapy products: A case study for adeno-associated viral vectors
Tanaka, T., Hanaoka, H., & Sakurai, S. (2020) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2020.08.002 · Cited by 27
Targeted Bottom-up Characterization of Recombinant Monoclonal Antibodies by Multidimensional LC/MS
Camperi, J., Guillarme, D., & Stella, C. (2020) · Analytical Chemistry · doi:10.1021/acs.analchem.0c02780 · Cited by 28
Multi-attribute method based characterization of antibody drug conjugates (ADC) at the intact and subunit levels
Martelet, A., Garrigue, V., Zhang, Y., Genêt, B., & Guttman, A. (2021) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2021.114094 · Cited by 27
Distinct and Quantitative Validation Method for Predictive Process Modeling with Examples of Liquid-Liquid Extraction Processes of Complex Feed Mixtures
Schmidt, A., & Strube, J. (2019) · Processes · doi:10.3390/pr7050298 · Cited by 26
Development of a miniature bioreactor model to study the impact of pH and DOT fluctuations on CHO cell culture performance as a tool to understanding heterogeneity effects at large‐scale
Zakrzewski, R., Lee, K., & Lye, G. J. (2022) · Biotechnology Progress · doi:10.1002/btpr.3264 · Cited by 25
Multiattribute Monitoring of Charge-Based Heterogeneity of Recombinant Monoclonal Antibodies Using 2D HIC-WCX-MS
Sarin, D., Kumar, S., & Rathore, A. S. (2022) · Analytical Chemistry · doi:10.1021/acs.analchem.2c02931 · Cited by 25
Using bispecific antibodies in forced degradation studies to analyze the structure–function relationships of symmetrically and asymmetrically modified antibodies
Evans, A. R., Capaldi, M. T., Goparaju, G. N., Colter, D. C., Shi, F. F., Aubert, S., Li, L., Mo, J., Lewis, M. J., Hu, P., et al. (2019) · mAbs · doi:10.1080/19420862.2019.1618675 · Cited by 24
In silico model-based characterization of metabolic response to harsh sparging stress in fed-batch CHO cell cultures
Hong, J. K., Yeo, H. C., Lakshmanan, M., Han, S.-H., Myoung, H., Han, M., & Lee, D. (2019) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2019.11.011 · Cited by 23
Clinical Immunogenicity Risk Assessment for a Fusion Protein
Sperinde, G. V., Montgomery, D. L., & Mytych, D. T. (2020) · The AAPS Journal · doi:10.1208/s12248-020-00447-y · Cited by 24
Integrated Process Analytical Platform for Automated Monitoring of Monoclonal Antibody N-Linked Glycosylation
Gyorgypal, A., & Chundawat, S. P. S. (2022) · Analytical Chemistry · doi:10.1021/acs.analchem.1c05396 · Cited by 22
Characterization of a Novel Bispecific Antibody With Improved Conformational and Chemical Stability
Manikwar, P., Mulagapati, S. H. R., Kasturirangan, S., Moez, K., Rainey, G. J., & Lobo, B. A. (2019) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2019.06.025 · Cited by 23
Automated multi‐attribute method sample preparation using high‐throughput buffer exchange tips
Ogata, Y., Quizon, P. M., Nightlinger, N. S., Sitasuwan, P., Snodgrass, C., Lee, L. A., Meyer, J. D., & Rogers, R. S. (2021) · Rapid Communications in Mass Spectrometry · doi:10.1002/rcm.9222 · Cited by 21
Digital Twins for scFv Production in Escherichia coli
Helgers, H., Hengelbrock, A., Schmidt, A., Vetter, F. L., Juckers, A., & Strube, J. (2022) · Processes · doi:10.3390/pr10050809 · Cited by 21
Identification and quantification of product-related quality attributes in bio-therapeutic monoclonal antibody via a simple, and robust cation-exchange HPLC method compatible with direct online detection of UV and native ESI-QTOF-MS analysis
Sankaran, P. K., Kabadi, P. G., Honnappa, C. G., Subbarao, M., Pai, H. V., Adhikary, L., & Palanivelu, D. V. (2018) · Journal of Chromatography B · doi:10.1016/j.jchromb.2018.10.019 · Cited by 20
The Botanical Drug Substance Crofelemer as a Model System for Comparative Characterization of Complex Mixture Drugs
Kleindl, P. A., Xiong, J., Hewarathna, A., Mozziconacci, O., Nariya, M. K., Fisher, A. C., Deeds, E. J., Joshi, S. B., Middaugh, C. R., Schöneich, C., et al. (2017) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2017.07.012 · Cited by 20
C-terminal lysine clipping of IgG1: impact on binding to human FcγRIIIa and neonatal Fc receptors
Faid, V., Leblanc, Y., Berger, M., Seifert, A., Bihoreau, N., & Chevreux, G. (2021) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2021.105730 · Cited by 19
Fc gamma receptor IIIb binding of individual antibody proteoforms resolved by affinity chromatography–mass spectrometry
Lippold, S., Knaupp, A., de Ru, A. H., Tjokrodirijo, R. T. N., van Veelen, P. A., van Puijenbroek, E., de Taeye, S. W., Reusch, D., Vidarsson, G., Wuhrer, M., et al. (2021) · mAbs · doi:10.1080/19420862.2021.1982847 · Cited by 19
Self-citation
Analytical tools for the characterization of deamidation in monoclonal antibodies
Spanov, B., Govorukhina, N. I., van de Merbel, N. C., & Bischoff, R. (2021) · Journal of Chromatography Open · doi:10.1016/j.jcoa.2021.100025 · Cited by 19
Streamlining the Characterization of Disulfide Bond Shuffling and Protein Degradation in IgG1 Biopharmaceuticals Under Native and Stressed Conditions
Coghlan, J., Benet, A., Kumaran, P., Ford, M., Veale, L., Skilton, S. J., Saveliev, S. V., & Schwendeman, A. A. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.862456 · Cited by 19
QbD-guided pharmaceutical development of Pembrolizumab biosimilar candidate PSG-024 propelled to industry meeting primary requirements of comparability to Keytruda®
Jaffaraghaei, M., Khanipour, F., Maghsoudi, A., Sarvestani, R., Mohammadian, M., Maleki, M., Havasi, F., Rahmani, H., Karagah, A.-H., & Kazemali, M. (2022) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2022.106171 · Cited by 21
Multi‐Dimensional Technology—Recent Advances and Applications for Biotherapeutic Characterization
Bouvarel, T., Camperi, J., & Guillarme, D. (2024) · Journal of Separation Science · doi:10.1002/jssc.202300928 · Cited by 20
An etanercept O-glycovariant with enhanced potency
Biel, T. G., Faison, T., Matthews, A. M., Zou, G., Ortega‐Rodriguez, U., Pegues, M. A., Azer, N., Gomez, F. D., Johnson, S., Rogstad, S., et al. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.03.002 · Cited by 18
Quality By Design: Approach to Analytical Method Validation
Dewi, M. K., Pratama, R., Arifka, M., & Chaerunisaa, A. Y. (2022) · Sciences of Pharmacy · doi:10.58920/sciphar01010033 · Cited by 18
Media supplementation for targeted manipulation of monoclonal antibody galactosylation and fucosylation
Wells, E. A., Song, L., Greer, M., Luo, Y., Kurian, V., Ogunnaike, B. A., & Robinson, A. S. (2020) · Biotechnology and Bioengineering · doi:10.1002/bit.27496 · Cited by 18
Evaluating the impact of media and feed combinations on CHO cell culture performance and monoclonal antibody (trastuzumab) production
Gyorgypal, A., Chaturvedi, A., Chopda, V., Zhang, H., & Chundawat, S. P. S. (2025) · Cytotechnology · doi:10.1007/s10616-024-00690-7 · Cited by 17
Detailed Analytical Characterization of a Bispecific IgG1 CrossMab Antibody of the Knob-into-Hole Format Applying Various Stress Conditions Revealed Pronounced Stability
Grunert, I., Heinrich, K., Ernst, J., Hingar, M., Briguet, A., Leiß, M., Wuhrer, M., Reusch, D., & Bulau, P. (2022) · ACS Omega · doi:10.1021/acsomega.1c06305 · Cited by 17
Biological Stability of Peptides/Proteins Therapeutic Agents
Salatin, S., Farjami, A., Siahi‐Shadbad, M., & Hamidi, S. (2023) · International Journal of Peptide Research and Therapeutics · doi:10.1007/s10989-023-10549-8 · Cited by 17
Quality by Design Approaches to Formulation Robustness—An Antibody Case Study
Wurth, C., Demeule, B., Mahler, H., & Adler, M. (2016) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2016.02.013 · Cited by 17
Host Cell Protein Clinical Safety Risk Assessment—An Updated Industry Review
Coye, L. H., Jones, M. A., Gaza‐Bulseco, G., Chitikila, C., Clavier, S., Fougeron, D., Grimaldi, C. M., Hurkmans, K., Hutchinson, R. W., Kellogg, B. A., et al. (2025) · Biotechnology and Bioengineering · doi:10.1002/bit.70029 · Cited by 16
Automated Online-Sampling Multidimensional Liquid Chromatography with Feedback-Control Capability as a Framework for Real-Time Monitoring of mAb Critical Quality Attributes in Multiple Bioreactors
Dunn, Z. D., Bohman, P., Quinteros, A., Sauerborn, B., Milman, F., Patel, M., Kargupta, R., Wu, S., Hornshaw, M. P., Barrientos, R. C., et al. (2023) · Analytical Chemistry · doi:10.1021/acs.analchem.3c03528 · Cited by 16
Targeted CQA analytical control strategy for commercial antibody products: Replacing ion-exchange chromatography methods for charge heterogeneity with multi-attribute monitoring
Evans, A. R., Mulholland, J., Lewis, M. J., & Hu, P. (2024) · mAbs · doi:10.1080/19420862.2024.2341641 · Cited by 16
Predicting the Long-Term Stability of Biologics with Short-Term Data
Dillon, M., Xu, J., Thiagarajan, G., Skomski, D., & Procopio, A. T. (2024) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c00609 · Cited by 16

Authors: Alt, N., Zhang, T. Y., Motchnik, P., Taticek, R., Quarmby, V., Schlothauer, T., Beck, H., Emrich, T., & Harris, R. J.
Affiliations: Genentech (US)
F. Hoffmann-La Roche AG (CH)
Corresponding author: Alt, Nadja
ORCID: Quarmby, Valerie
Schlothauer, Tilman
Emrich, Thomas
Venue: Biologicals
Publisher: Elsevier BV
Published: 2016-09
Volume: 44
Issue: 5
Pages: 291-305
ISSN: 1045-1056 (ISSN-L)
DOI: 10.1016/j.biologicals.2016.06.005
OpenAlex: W2498896723
Cited by: 294
References: 54
Citations by year: 2026: 27 · 2025: 31 · 2024: 39 · 2023: 31 · 2022: 39 · 2021: 29 · 2020: 35 · 2019: 18 · 2018: 18 · 2017: 19 · 2016: 7
FWCI: 1.87
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Biologicals (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein purification and stability
Life Sciences › Immunology and Microbiology › Immunology › Biosimilars and Bioanalytical Methods
Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
Keywords: critical quality attributes, quality by design, monoclonal antibodies, biopharmaceuticals, risk assessment, risk prioritization, recombinant protein expression, drug safety and efficacy, process knowledge
MeSH terms: Animals, Antibodies, Monoclonal, Humans, Quality Control, Recombinant Proteins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Determination of critical quality attributes for monoclonal antibodies using quality by design principles

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks